Farmas USA

TRx = Scripts/Recetas totales semana pasada

NRx = Scripts/Recetas en clientes nuevos semana pasada

Queda muy bien eso de que no te fias de los analisis de casi nadie, eso no se si signica que dejas abierta la puerta a algun analista del que si te fias ... o es una manera de hablar queriendo decir que tampoco todos los analistas consideras que son una perdida de tiempo?

Porque cada vez que dices que el dolar/euro se va para arriba o para abajo es porque replicas lo que lees de algun analista ...

Buenos días.

¿Alguien lleva NBS (NeoStem) en cartera? ¿Cómo la veis?

http://globenewswire.com/news-release/2015/05/21/738272/10135412/en/Turning-Cancer-Against-Itself-Major-Grant-Advances-Pioneering-Melanoma-Therapy-at-NeoStem.html

"NeoStem's belief is that if the Phase 3 trial is successful, and the therapy is then approved by the FDA, it could be a breakthrough in the treatment of metastatic melanoma patients and available as early as 2018. "

tiene un PO  de 13 pavos

NBS

IRB Approves Additional Enrollment in Cellceutix’s Clinical Trial of New Cancer Drug Candidate for Solid Tumors

Company to Seek FDA Guidance to Pursue Phase 2/3 Trial of Kevetrin

BEVERLY, MA--(Marketwired - May 22, 2015)-- Cellceutix Corporation (OTC: CTIX) (the "Company"), a clinical stage biopharmaceutical company developing innovative therapies with oncology, dermatology, and antimicrobial applications, is pleased to announce that the Institutional Review Board (“IRB”) overseeing the Company’s Phase 1 clinical trial of Kevetrin for the treatment of advanced solid tumors being conducted at Harvard University’s Dana-Farber Cancer Institute and partner Beth Israel Deaconess Medical Center has approved the amended protocol to allow additional patient enrollment to the study.

The original protocol for the trial specified 40 patients to be enrolled. Due to maximum tolerated dose (“MTD”) not yet being identified and data indicating that the effect of Kevetrin on p53, a key tumor suppressor protein often referred to as the “Guardian of the Genome,” is dose dependent as expected, Cellceutix requested an amendment to the protocol to continue to evaluate administration of Kevetrin at higher doses. The trial is currently in its eleventh cohort, with one patient (the 40th in the trial) having received two infusions of Kevetrin at 750 mg/m2. The Company has been advised that screening of additional patients is underway and they are expected to be enrolled into the study.

“We interpret the IRB approval as a strong vote of confidence as to the safety and potential impact of Kevetrin to deliver a meaningful effect on p53, a protein that researchers have been trying for decades to safely revitalize to unlock better clinical outcomes in the millions of cancer patients where the p53 pathway is damaged,” commented Leo Ehrlich, Chief Executive Officer of Cellceutix. “We could have concluded the trial with the completion of the target enrollment, but we have a novel drug delivering compelling data that we want to push to the limit to best direct the scope of future studies. With regards to cancer, the U.S. Food and Drug Administration is doing a tremendous job with initiatives, programs, and support of trial designs to expedite the development of safe and effective new cancer treatments to get them to patients that so desperately need them. Effectively, this is blurring the lines of traditional clinical trial phases such as 1, 2 and 3 for promising new therapies, and we believe Kevetrin fits that mold as an activator of p53. We are privileged to have the experts at Dana-Farber, Beth Israel Deaconess, and partners conducting the research that is helping us chart a course to try and capitalize on this shifting regulatory trend by meticulously defining which cancer tumor types may be most beneficially impacted by Kevetrin.”

With 40 patients enrolled, Cellceutix feels that it has more than ample data supporting the safety of Kevetrin as well as evidence of possible therapeutic benefits. As such, the Company is moving forward with confidence in preparing documentation for a meeting with the Food and Drug Administration seeking to initiate a Phase 2/3 trial of Kevetrin against a specific type of cancer.

CTIX

GALE

Galena Biopharma to Present GALE-401 (Anagrelide Controlled Release) Phase 2 Clinical Trial Data at the European Hematology Association 20th Congress

Details of the poster presentation are as follows:

Abstract #: P671
Title: Phase 2 Study of a Novel Controlled-Release Formulation of Anagrelide (GALE-401) in Subjects with Myeloproliferative Neoplasm (MPN)-Related Thrombocytosis
Session Title: Myeloproliferative neoplasms - Clinical 2
Date: Saturday, June 13, 2015
Time: 5:15 p.m. to 6:45 p.m. local time
Location: Poster area (Hall C)

Hola,

No suelo escribir mucho, pero os leo a varias veces al día.

Como ya he comentado en alguna ocasión, solo tengo una farma, en 4 brokeres diferentes, por eso de la diversificación. No os digo cual porque cuando suba a tope, quiero todo los dineros para mi, nada para vosotros.

El caso es que ahora estaba aburridillo, y me he dicho.... con la de compraventas que he hecho de NVAX :-) , desde que la pillé a 6 leurines, seguro que si me hubiera estado quieto hubiera ganado más. De hecho dejé de intentar tradearla porque estaba convencido que había hecho el mico.

Cómo es el celebro humano!!, Seguro de que había dejado de ganar, y ahora veo que, todo lo contrario, desde los 6 leurines, y sólamente en en esta cuenta, casi la he doblado.Soy una máquina.

Pues bien, tras mi última compra, me dije: Ahi se queda, que le den, demasiado tiempo perdido para ganar menos. Ya llueva truene o granize, que esto no lo vendo hasta que no vengan a mi casa los de Feizer o Novartis a amenazarme a mi casa. Fue el 23 de Marzo, a 8,06 USD , estoy viendo que mi cuenta ha menguado!! Guat de fac!!?! Mierda de Euro Dolar, no?

Bueno, pues asi a primeras no me salen las cuentas. 9:8 > 1.12:1.08. Voy a sacar el lapicero y hago cuentas. 7,39 euros de compra, hoy está a 7.91 leurines.

Pero si sale positiva!! MADERFAKERS!!!

Efectivamente, tengo la cuentecilla en rojete, eso es así.Es más,segun la plataforma Degiro, el diferencial del día es de -30 euros. Pero si hoy aún no ha cotizado, y el mínimo de la sesion eurodolarin 1.11 , ahora , 1.12 redondeando, para perder 30 eurines debería haber 3000 pavetes.

En fin, es solo una reflexión de aburrimiento, no dudo que algo se me escapa, seguramente lo mismo que mi celebro me engañó con lo del tradeo, me estará ocultando alguna operación ruinosa (Por ejemplo un ETF apalancado por 4 sobre el WTI la cual ha sido tan ruinosa que dudo que se pueda obtener menos rentabilidad con un ETF en una semana. En serio, estoy convencido, hasta un 50% de 4 a 2)
Y ya de paso me meto un poco con Degirete, que vaya bulsit de plataforma.

Un saludo, y suerte para esta tarde, os recomiendo cerrar las posiciones especulativas abiertas, los sondeos de mi pueblo para este domingo auguran alta volatilidad en el Nasdaq

Un saludo
PD. Perdonadme por las palabrotas, pero es que estoy perfecionando el ingles con el GTA V y me salen solas, crakers